PDF(Pubmed)
Abstract：
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases and its prevalence is increasing worldwide. It is reported that NAFLD is associated with colorectal polyps. Since identifying NAFLD in its early stages could prevent possible disease progression to cirrhosis and decrease the risk of HCC by early intervention, patients with colorectal polyp may thus be considered a target group for screening NAFLD. This study aimed to investigate the potential of serum microRNAs (miRNAs) in identifying NAFLD for colorectal polyp patients. Serum samples were collected from 141 colorectal polyp patients, of which 38 had NAFLD. The serum level of eight miRNAs was determined by quantitative PCR and delta Ct values of different miRNA pairs which were compared between NAFLD and control groups. A miRNA panel was formulated from candidate miRNA pairs by multiple linear regression model and ROC analysis was performed to evaluate its diagnostic potential for NAFLD. Compared to the control group, the NAFLD group showed significantly lower delta Ct values of miR-18a/miR-16 (6.141 vs. 7.374, p = 0.009), miR-25-3p/miR-16 (2.311 vs. 2.978, p = 0.003), miR-18a/miR-21-5p (4.367 vs. 5.081, p = 0.021) and miR-18a/miR-92a-3p (8.807 vs. 9.582, p = 0.020). A serum miRNA panel composed of these four miRNA pairs significantly identified NAFLD in colorectal polyp patients with an AUC value of 0.6584 (p = 0.004). The performance of the miRNA panel was further improved to an AUC value of 0.8337 (p < 0.0001) when polyp patients with other concurrent metabolic disorders were removed from the analysis. The serum miRNA panel is a potential diagnostic biomarker for screening NAFLD in colorectal polyp patients. This serum miRNA test could be performed for colorectal polyp patients for early diagnosis and for prevention of the disease from progressing into more advanced stages.
摘要：
非酒精性脂肪性肝病（NAFLD）是最常见的慢性肝病之一，其患病率在全球范围内呈上升趋势。据报道，NAFLD与结直肠息肉有关。由于识别NAFLD在其早期阶段可以防止可能的疾病进展到肝硬化，并通过早期干预降低HCC的风险，因此,结直肠息肉患者可被视为筛查NAFLD的目标人群.本研究旨在探讨血清microRNAs(miRNAs)在鉴别结直肠息肉患者NAFLD中的应用价值。收集141例结直肠息肉患者的血清样本，其中38人患有NAFLD。通过定量PCR测定8个miRNA的血清水平,并比较NAFLD组和对照组之间不同miRNA对的δCt值。通过多元线性回归模型从候选miRNA对配制miRNA组,并进行ROC分析以评估其对NAFLD的诊断潜力。与对照组相比,NAFLD组显示miR-18a/miR-16的ΔCt值显着降低（6.141vs.7.374,p=0.009),miR-25-3p/miR-16（2.311vs.2.978，p=0.003），miR-18a/miR-21-5p（4.367vs.5.081，p=0.021）和miR-18a/miR-92a-3p（8.807vs.9.582,p=0.020)。由这四个miRNA对组成的血清miRNA组显著鉴定了结肠直肠息肉患者中的NAFLD,AUC值为0.6584(p=0.004)。当具有其他并发代谢紊乱的息肉患者从分析中移除时,miRNA组的性能进一步改善至0.8337(p<0.0001)的AUC值。血清miRNA组是用于在结直肠息肉患者中筛查NAFLD的潜在诊断生物标志物。该血清miRNA测试可用于结肠直肠息肉患者的早期诊断和预防疾病进展到更晚期。
